Eplerenone May Reach Market Before Pfizer Merger: Co-Promotion Planned

Pfizer and Pharmacia may co-promote the selective aldosterone blocker eplerenone for hypertension by the end of this year if FDA approval for the product precedes the pending merger between the firms